BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20001863)

  • 21. Transcription factor CHF1/Hey2 regulates neointimal formation in vivo and vascular smooth muscle proliferation and migration in vitro.
    Sakata Y; Xiang F; Chen Z; Kiriyama Y; Kamei CN; Simon DI; Chin MT
    Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2069-74. PubMed ID: 15345511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload.
    Zhou H; Bian ZY; Zong J; Deng W; Yan L; Shen DF; Guo H; Dai J; Yuan Y; Zhang R; Lin YF; Hu X; Li H; Tang QZ
    Hypertension; 2012 Sep; 60(3):802-9. PubMed ID: 22851736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NF-kappaB activation is required for adaptive cardiac hypertrophy.
    Zelarayan L; Renger A; Noack C; Zafiriou MP; Gehrke C; van der Nagel R; Dietz R; de Windt L; Bergmann MW
    Cardiovasc Res; 2009 Dec; 84(3):416-24. PubMed ID: 19620128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy.
    Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K
    Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
    Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
    Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-206 Mediates YAP-Induced Cardiac Hypertrophy and Survival.
    Yang Y; Del Re DP; Nakano N; Sciarretta S; Zhai P; Park J; Sayed D; Shirakabe A; Matsushima S; Park Y; Tian B; Abdellatif M; Sadoshima J
    Circ Res; 2015 Oct; 117(10):891-904. PubMed ID: 26333362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.
    Sun B; Huo R; Sheng Y; Li Y; Xie X; Chen C; Liu HB; Li N; Li CB; Guo WT; Zhu JX; Yang BF; Dong DL
    Hypertension; 2013 Feb; 61(2):352-60. PubMed ID: 23248151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch signaling regulates Hey2 expression in a spatiotemporal dependent manner during cardiac morphogenesis and trabecular specification.
    Miao L; Li J; Li J; Tian X; Lu Y; Hu S; Shieh D; Kanai R; Zhou BY; Zhou B; Liu J; Firulli AB; Martin JF; Singer H; Zhou B; Xin H; Wu M
    Sci Rep; 2018 Feb; 8(1):2678. PubMed ID: 29422515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulator of G Protein Signaling 6 Facilities Cardiac Hypertrophy by Activating Apoptosis Signal-Regulating Kinase 1-P38/c-JUN N-Terminal Kinase 1/2 Signaling.
    Huang Z; Shu J; Jiang W; Jiang M; Lu Y; Dai H; Xu N; Yuan H; Cai J
    J Am Heart Assoc; 2018 Oct; 7(19):e009179. PubMed ID: 30371330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of the hypoxia response pathway protects against age-induced cardiac hypertrophy.
    Röning T; Magga J; Laitakari A; Halmetoja R; Tapio J; Dimova EY; Szabo Z; Rahtu-Korpela L; Kemppi A; Walkinshaw G; Myllyharju J; Kerkelä R; Koivunen P; Serpi R
    J Mol Cell Cardiol; 2022 Mar; 164():148-155. PubMed ID: 34919895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload.
    Jiang DS; Li L; Huang L; Gong J; Xia H; Liu X; Wan N; Wei X; Zhu X; Chen Y; Chen X; Zhang XD; Li H
    Hypertension; 2014 Jul; 64(1):77-86. PubMed ID: 24732887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dec1 deficiency protects the heart from fibrosis, inflammation, and myocardial cell apoptosis in a mouse model of cardiac hypertrophy.
    Li X; Le HT; Sato F; Kang TH; Makishima M; Zhong L; Liu Y; Guo L; Bhawal UK
    Biochem Biophys Res Commun; 2020 Nov; 532(4):513-519. PubMed ID: 32896382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TEAD-1 overexpression in the mouse heart promotes an age-dependent heart dysfunction.
    Tsika RW; Ma L; Kehat I; Schramm C; Simmer G; Morgan B; Fine DM; Hanft LM; McDonald KS; Molkentin JD; Krenz M; Yang S; Ji J
    J Biol Chem; 2010 Apr; 285(18):13721-35. PubMed ID: 20194497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.
    Kook H; Lepore JJ; Gitler AD; Lu MM; Wing-Man Yung W; Mackay J; Zhou R; Ferrari V; Gruber P; Epstein JA
    J Clin Invest; 2003 Sep; 112(6):863-71. PubMed ID: 12975471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload.
    Wu G; Liu Y; Huang H; Tang Y; Liu W; Mei Y; Wan N; Liu X; Huang C
    Cardiovasc Res; 2015 Jul; 107(2):203-15. PubMed ID: 26077624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
    Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X
    Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors.
    Rutenberg JB; Fischer A; Jia H; Gessler M; Zhong TP; Mercola M
    Development; 2006 Nov; 133(21):4381-90. PubMed ID: 17021042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy.
    Deng KQ; Zhao GN; Wang Z; Fang J; Jiang Z; Gong J; Yan FJ; Zhu XY; Zhang P; She ZG; Li H
    Circulation; 2018 Apr; 137(14):1486-1504. PubMed ID: 29229612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis.
    Yoon PO; Lee MA; Cha H; Jeong MH; Kim J; Jang SP; Choi BY; Jeong D; Yang DK; Hajjar RJ; Park WJ
    J Mol Cell Cardiol; 2010 Aug; 49(2):294-303. PubMed ID: 20430035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.
    Flevaris P; Khan SS; Eren M; Schuldt AJT; Shah SJ; Lee DC; Gupta S; Shapiro AD; Burridge PW; Ghosh AK; Vaughan DE
    Circulation; 2017 Aug; 136(7):664-679. PubMed ID: 28588076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.